Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03706261 · ClinicalTrials.gov registry record · Phase 1
Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults
A Phase 1 study of Alzheimer Disease, sponsored by Adam Brickman.
- Completed
- Registry status
- Phase 1
- Development phase
- 145
- Enrollment target
- 1
- Study location
NCT03706261: Completed Phase 1 study of Alzheimer Disease, sponsored by Adam Brickman.
NCT03706261 is a Phase 1 study of Alzheimer Disease that has completed, run by Adam Brickman. The registered enrollment target is 145 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03706261, a Phase 1 study of Alzheimer Disease, has completed, sponsored by Adam Brickman.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 145 participants
- Enrollment target
- 1
- Study location
Study Summary
The study employs tau positron emission tomography (PET) imaging in a well-characterized multi-racial/ethnic cohort to examine the extent to which tau pathology is associated with cognition, differences in tau pathology across racial/ethnic groups, and the relationship between MRI markers of small-vessel cerebrovascular disease and tau pathology. The study also investigates amyloid-dependent tau spreading.
Primary Outcome
Regional standardized uptake value ratio (SUVR) for 18F-MK-6240 will be calculated to investigate associations with measures of memory, olfactory function, and cerebrovascular disease.
Conditions Studied
Interventions
- DRUG 18F-MK-6240
- DRUG 18F-Florbetaben
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2019-03-22 |
| Est. Completion | 2023-07-14 |
| Phase | Phase 1 |
What the finished NCT03706261 record still lists
NCT03706261 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which 18F-MK-6240 is the first listed.
NCT03706261 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03706261 about?
NCT03706261 is a clinical study titled "Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults". The study employs tau positron emission tomography (PET) imaging in a well-characterized multi-racial/ethnic cohort to examine the extent to which tau pathology is associated with cognition, differences in tau pathology across racial/ethnic groups, and the relationship between MRI markers of small-v...
What is the current status of trial NCT03706261?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 145 participants. The study started on 2019-03-22. Estimated completion is 2023-07-14.
What conditions does trial NCT03706261 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT03706261?
The interventions under investigation include: 18F-MK-6240 (DRUG), 18F-Florbetaben (DRUG).
Who is sponsoring clinical trial NCT03706261?
This trial is sponsored by Adam Brickman, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03706261 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03706261's enrollment target sits among peer trials
145 132nd of 306 higher than 175 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
RECRUITING · Phase 1
-
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
RECRUITING · Phase 1
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Assess Fibrin in Brains With AD/ADRD
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI